Half Yearly Report and Accounts

• Revenue unchanged, loss up 135% to $55.6M
• Net tangible assets per share increased to 62.6 cents
• Clarity Pharmaceuticals Europe SA wound up, resulting in loss of control

Clarity Pharmaceuticals Ltd has released its financial results for the half-year ended 31 December 2025. Revenue from ordinary activities remained unchanged from the previous corresponding period, while the loss from ordinary activities after tax attributable to the owners of the company increased by 135% to $55,533,000. The overall loss for the year attributable to the owners of Clarity Pharmaceuticals Ltd was $55,632,000, up 136% from the prior period. There were no dividends paid, recommended, or declared during the current financial period. The net tangible assets per ordinary security increased from 39.7 cents in the previous period to 62.6 cents. On 31 December 2025, Clarity Pharmaceuticals Europe SA (CPEU) was wound up, resulting in a loss of control. The consolidated financial statements for the half-year ended 31 December 2025 have been reviewed by Grant Thornton, who have issued an unmodified opinion.